Lancet Microbe最新文献

{"title":"Pandemic risk characterisation of zoonotic influenza A viruses using the Tool for Influenza Pandemic Risk Assessment (TIPRA)","authors":"Reina Yamaji MD ,&nbsp;Wenqing Zhang MD ,&nbsp;Akiko Kamata DVM ,&nbsp;Cornelia Adlhoch PhD ,&nbsp;David E Swayne PhD ,&nbsp;Dmitriy Pereyaslov MD ,&nbsp;Dayan Wang PhD ,&nbsp;Gabriele Neumann PhD ,&nbsp;Gounalan Pavade PhD ,&nbsp;Prof Ian G Barr PhD ,&nbsp;Prof Malik Peiris PhD ,&nbsp;Richard J Webby PhD ,&nbsp;Prof Ron A M Fouchier PhD ,&nbsp;Sophie Von Dobschütz PhD ,&nbsp;Thomas Fabrizio PhD ,&nbsp;Prof Yuelong Shu PhD ,&nbsp;Magdi Samaan DVM","doi":"10.1016/j.lanmic.2024.100973","DOIUrl":"10.1016/j.lanmic.2024.100973","url":null,"abstract":"<div><div>A systematic risk assessment approach is essential for evaluating the relative risk of influenza A viruses (IAVs) with pandemic potential. To achieve this, the Tool for Influenza Pandemic Risk Assessment (TIPRA) was developed under the Global Influenza Programme of WHO. Since its release in 2016 and update in 2020, TIPRA has been used to assess the pandemic risk of 11 zoonotic IAVs across ten evaluation rounds. Notably, A(H7N9), A(H9N2), and A(H5) clade 2.3.4.4 viruses were re-evaluated owing to changes in epidemiological characteristics or virus properties. A(H7N9) viruses had the highest relative risk at the time of assessment, highlighting the importance of continuous monitoring and reassessment as changes in epidemiological trends within animal and human populations can alter risk profiles. The knowledge gaps identified throughout the ten risk assessments should help to guide the efficient use of resources for future research, including surveillance. The TIPRA tool reflects the One Health approach and has proven crucial for closely monitoring virus dynamics in both human and non-human populations to enhance preparedness for potential IAV pandemics.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 3","pages":"Article 100973"},"PeriodicalIF":20.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing microbiome-based biomarkers: challenges and opportunities","authors":"Rajesh Kanna Gopal ,&nbsp;Pitchaipillai Sankar Ganesh ,&nbsp;Naji Naseef Pathoor ,&nbsp;Akshaya Viswanathan","doi":"10.1016/j.lanmic.2024.101032","DOIUrl":"10.1016/j.lanmic.2024.101032","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 3","pages":"Article 101032"},"PeriodicalIF":20.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK","authors":"Nicola Borthwick PhD ,&nbsp;Natalia Fernandez MSc ,&nbsp;Peter J Hayes PhD ,&nbsp;Edmund G-T Wee PhD ,&nbsp;Belkis M Akis Yildirim MD ,&nbsp;Andrea Baines BSc ,&nbsp;Megan Baker BA ,&nbsp;Nicholas Byard MSc ,&nbsp;Oliver Conway BA ,&nbsp;Molly Glaze MSc ,&nbsp;Daniel Jenkin MRCP ,&nbsp;Colin Larkworthy HND ,&nbsp;Michael Luciw PGCert ,&nbsp;Abigail Platt ,&nbsp;Ian Poulton DipHE ,&nbsp;Merin Thomas MSc ,&nbsp;Jack Quaddy MSc ,&nbsp;Marion Watson PhD ,&nbsp;Alison Crook PhD ,&nbsp;Paola Cicconi MD ,&nbsp;Tomáš Hanke PhD","doi":"10.1016/j.lanmic.2024.100956","DOIUrl":"10.1016/j.lanmic.2024.100956","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;An HIV-1 vaccine is long overdue. Although vaccine research focuses on the induction of broadly neutralising antibodies, challenging infections such as HIV-1 could require parallel induction of protective T cells. It is important to recognise that not all T cells contribute to protection equally. Previously, we developed a T-cell immunogen-based bivalent mosaic vaccine, HIVconsvX, delivered by vaccine vectors ChAdOx1 and modified vaccinia Ankara. In this study, we tested the HIVconsvX vaccine regimen for the first time in humans. Other ongoing trials will assess the contribution of the vaccine-induced killer T cells to the control of HIV-1.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;HIV-CORE 005.2 was an open-label, dose-escalation, first-in-human, phase 1 trial done at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK. Eligible participants were healthy volunteers aged 18–65 years living without HIV-1 and at a low likelihood of acquiring it. Because it was the first administration of ChAdOx1.tHIVconsv1 (C1) to humans, participants were assigned stepwise to two groups. Volunteer group 1 received a low dose of C1 on enrolment. Following a satisfactory safety review 7 days after vaccination, volunteer group 2 received a full dose of C1 boosted by vaccines MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) 4 weeks later in regimen C1-M3M4 and were followed up until day 140. Focusing on the full vaccine doses in group 2, the primary outcome was the local and systemic safety of the vaccine. The secondary outcome was the frequency and breadth of epitope recognition by vaccine-induced T cells determined by IFN-γ ELISPOT assay using peripheral blood mononuclear cells (PBMC) at peak (1 and 2 weeks after the M3M4 boost) and at the end of the study, assessed against volunteer’s pre-vaccination levels. The HIV-CORE 005.2 trial is registered at &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT04586673&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;) and is closed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between July 3, 2021, and Aug 3, 2022, 13 participants were recruited and assigned to group 1 (n=3) and group 2 (n=10). Low-dose C1 was safe and well tolerated in group 1, and all three vaccine components were well tolerated in volunteer group 2. There were no serious adverse events. Local and systemic reactogenicities were consistent with intramuscular needle administration of immunogenic substances. All volunteers responded, and their vaccine-elicited T-cell frequencies peaked at a median of 4433 (IQR 2750–5820) IFN-γ spot-forming units per 10&lt;sup&gt;6&lt;/sup&gt; PBMC and recognised a median of 9 (IQR 9-10) peptide pools out of 10, indicating that the responses were broadly specific and each vaccine recipient targeted at least nine epitopes on HIV-1. These frequencies were 7·4 times lower by day 140 (ie, 3 months later). T cells proliferated upon antigen re-exposure and displayed multi","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 3","pages":"Article 100956"},"PeriodicalIF":20.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial","authors":"Yi Hu PhD ,&nbsp;Zhen-Yu Zhang MS ,&nbsp;Prof Fen Wang PhD ,&nbsp;Prof Kun Zhuang PhD ,&nbsp;Xin Xu MS ,&nbsp;Dong-Sheng Liu MS ,&nbsp;Hui-Zhen Fan MS ,&nbsp;Li Yang MS ,&nbsp;Prof Kui Jiang PhD ,&nbsp;Prof De-Kui Zhang PhD ,&nbsp;Prof Long Xu PhD ,&nbsp;Jian-Hua Tang MS ,&nbsp;Prof Xue-Mei Liu PhD ,&nbsp;Cong He PhD ,&nbsp;Prof Xu Shu PhD ,&nbsp;Prof Yong Xie PhD ,&nbsp;Prof James Y W Lau MD ,&nbsp;Prof Yin Zhu PhD ,&nbsp;Prof Yi-Qi Du PhD ,&nbsp;David Y Graham MD ,&nbsp;Prof Nong-Hua Lu MS","doi":"10.1016/j.lanmic.2024.100975","DOIUrl":"10.1016/j.lanmic.2024.100975","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Vonoprazan and amoxicillin (VA) dual therapy as a mainstream &lt;em&gt;Helicobacter pylori&lt;/em&gt; regimen has gained momentum worldwide, but the optimum dosages remain unclear. We aimed to compare the efficacy and safety of VA dual therapy with 2 g amoxicillin or 3 g amoxicillin, and to assess the short-term effects of therapy on the gut microbiota and antibiotic resistome.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We conducted an open-label, non-inferiority randomised controlled trial at 12 centres in China. Individuals infected with &lt;em&gt;H pylori&lt;/em&gt;, aged 18–70 years, and without previous eradication therapy were recruited. Participants were randomly assigned at a 1:1 ratio (block size of six) to receive vonoprazan (20 mg twice a day) with either low-dose amoxicillin (1 g twice a day; LVA therapy) or high-dose amoxicillin (1 g three times a day; HVA therapy) for 14 days. Gastric biopsies were collected before treatment for detection of antibiotic resistance. Stool samples were collected at baseline, week 2, and week 8–10 for shotgun metagenomic sequencing. The primary outcome was the eradication rate of &lt;em&gt;H pylori&lt;/em&gt;, assessed by &lt;sup&gt;13&lt;/sup&gt;C urea breath test, in both intention-to-treat and per-protocol analyses. Secondary outcomes were adverse events, adherence, antibiotic resistance, and alterations to the gut microbiota and antibiotic resistome. The margin used to establish non-inferiority was –0·10. The trial was registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT05649709&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between Feb 13, 2023, and Jan 25, 2024, 504 patients (204 [40%] male and 300 [60%] female; mean age 43 years [SD 13]) were randomly assigned to LVA therapy or HVA therapy (n=252 in each group). No infections were resistant to amoxicillin. The &lt;em&gt;H pylori&lt;/em&gt; eradication rate was 85·3% (215 of 252; 95% CI 80·4 to 89·2) in the LVA group and 86·5% (218 of 252; 81·7 to 90·2) in the HVA group in the intention-to-treat analysis (p=0·70) and 88·8% (213 of 240; 84·1 to 92·2) and 92·4% (218 of 236; 88·3 to 95·1), respectively, in the per-protocol analysis (p=0·18). The efficacy of LVA was non-inferior to HVA in the intention-to-treat analysis (risk difference –1·2%, 95% CI –7·3 to 4·9, p=0·0022) and the per-protocol analysis (–3·6%, –9·0 to 1·7, p=0·0085). 31 (12%) patients in the LVA group and 43 (17%) patients in the HVA group reported adverse events. Adherence to therapy was 97% in the LVA group and 96% in the HVA group. The diversity of gut microbiota decreased after treatment but was restored to baseline at week 8–10 in both groups. The abundance of beta-lactam-related resistance genes was increased at week 2 after treatment, and was restored to pretreatment level at week 8–10 for the LVA group but not the HVA group.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;LVA dual therapy was effective and non-inferior to HVA dual therapy ","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 3","pages":"Article 100975"},"PeriodicalIF":20.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combating regional outbreaks: One Health strategy integrating reverse microbial aetiology to avert global pandemics.","authors":"Xulong Lang, Jianhai Yin, Yang Sun","doi":"10.1016/j.lanmic.2025.101091","DOIUrl":"https://doi.org/10.1016/j.lanmic.2025.101091","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101091"},"PeriodicalIF":20.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected increase in ompA-genotype L1 variants responsible for anorectal lymphogranuloma venereum in France.","authors":"Arabella Touati, Cécile Laurier-Nadalié, Cécile Bébéar, Olivia Peuchant","doi":"10.1016/j.lanmic.2025.101097","DOIUrl":"https://doi.org/10.1016/j.lanmic.2025.101097","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101097"},"PeriodicalIF":20.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of clinical donor characteristics on the success of faecal microbiota transplantation for patients in Denmark with Clostridioides difficile infection: a single-centre, prospective cohort study.","authors":"Anne Karmisholt Grosen, Susan Mikkelsen, Lotte Aas Hindhede, Sara Ellegaard Paaske, Simon Mark Dahl Baunwall, Mette Mejlby Hansen, Jens Frederik Dahlerup, Martin Steen Mortensen, Tine Rask Licht, Jens Kjærgaard Boldsen, Lise Tornvig Erikstrup, Christian Lodberg Hvas, Christian Erikstrup","doi":"10.1016/j.lanmic.2024.101034","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101034","url":null,"abstract":"<p><strong>Background: </strong>Faecal microbiota transplantation (FMT) is an effective treatment for patients with recurrent Clostridioides difficile infection, but donor selection can influence its clinical success. We aimed to investigate the effect of clinical donor characteristics on FMT outcomes in patients with C difficile infection.</p><p><strong>Methods: </strong>In this single-centre, prospective cohort study, we included all donors who fulfilled the national criteria for faeces donation and delivered donations to the Centre for Faecal Microbiota Transplantation, Aarhus University Hospital, Denmark, between May 2, 2016, and Oct 31, 2023, and corresponding recipients treated with one-dose FMT for primary or recurrent C difficile infection. In mixed-effects models, we evaluated the effect of donor sex, age, BMI, smoking status, donation stool consistency, total donation weight, antibiotic use, Helicobacter pylori carriage, birth mode, donor-recipient sex concordance, and the alpha diversity of faeces donations on FMT outcomes in recipients. The primary outcome was the resolution of diarrhoea associated with C difficile infection in patients 8 weeks after FMT.</p><p><strong>Findings: </strong>Among 145 blood donors who also donated faeces, 115 (79·3%) were men and 30 (20·7%) were women. 90 (62·1%) provided faeces for 1351 evaluable FMTs in 952 patients with C difficile infection. 1037 (76·8%) FMTs were administered through oral capsules, 151 (11·2%) via colonoscopy, and 163 FMTs (12·1%) via nasojejunal tube. Antibiotic use 3-12 months before donation decreased the effectiveness of FMT (odds ratio 0·55 [95% CI 0·33-0·91]; p=0·019). Compared with donations with a Bristol Stool Form Scale (BSFS) score of 3, donations with a score of 4 (odds ratio 1·38 [95% CI 1·04-1·83]; p=0·024) and 5 or above (2·89 [1·33-6·26]; p=0·0072) showed improved FMT effectiveness. Donor sex, BMI, smoking status, H pylori carriage, birth mode, total donation weight, and donor-recipient sex concordance did not affect FMT outcomes.</p><p><strong>Interpretation: </strong>Expanding current donor selection criteria to avoid antibiotic use in the 12 months preceding donation and including donations with a BSFS score of 5 might improve FMT outcomes for patients with C difficile infection. Our findings call for the revision of current clinical donor screening practices, and future studies could further optimise the criteria for selecting optimal faeces donors.</p><p><strong>Funding: </strong>Innovation Fund Denmark.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101034"},"PeriodicalIF":20.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Call for prudent use of the term hypervirulence in carbapenem-resistant Klebsiella pneumoniae.","authors":"Yongqiang Yang, Alan McNally, Zhiyong Zong","doi":"10.1016/j.lanmic.2025.101090","DOIUrl":"https://doi.org/10.1016/j.lanmic.2025.101090","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101090"},"PeriodicalIF":20.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of non-human primate models in accelerating research and developing countermeasures against Zika virus infection.","authors":"Amanda Li, Lark L Coffey, Emma L Mohr, Jessica Raper, Ann Chahroudi, Karla K Ausderau, Matthew T Aliota, Thomas C Friedrich, Ann M Mitzey, Michelle R Koenig, Thaddeus G Golos, Hannah K Jaeger, Victoria H J Roberts, Jamie O Lo, Jessica L Smith, Alec J Hirsch, Daniel N Streblow, Christina M Newman, David H O'Connor, Eve M Lackritz, Koen K A Van Rompay, Kristina M Adams Waldorf","doi":"10.1016/j.lanmic.2024.101030","DOIUrl":"10.1016/j.lanmic.2024.101030","url":null,"abstract":"<p><p>Zika virus, a mosquito-transmitted orthoflavivirus, has become a pathogen of global health concern ever since the virus caused an epidemic in Brazil in 2015 associated with approximately 700 000 laboratory-confirmed cases of congenital microcephaly. The subsequent spread of the epidemic in 2016 resulted in a wide spectrum of congenital neurological, ophthalmological, and developmental abnormalities across the Americas, Africa, and Asia. In this context, non-human primate models have become essential tools for Zika virus research to understand the pathogenesis of congenital brain injury and perinatal complications and for developing and testing medical countermeasures such as vaccines, diagnostics, and therapeutics. Fetal brain injury has been observed across various non-human primate species and is influenced by factors such as the Zika virus strain, gestational age at inoculation, and inoculation dose and route. Miscarriages are also seen as common outcomes of first trimester Zika virus infections. This Series paper reviews the diverse non-human primate models currently used for Zika virus research to mitigate the public health effects of future Zika virus epidemics.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101030"},"PeriodicalIF":20.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specimen and data sharing to advance research and development on Zika virus.","authors":"Rosanna W Peeling, Noah T Fongwen, Maria G Guzman, Jairo Andres Méndez-Rico, Michael Selorm Avumegah, Thomas Jaenisch, Eve M Lackritz","doi":"10.1016/j.lanmic.2024.101057","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101057","url":null,"abstract":"<p><p>For diseases with epidemic potential, specimen and data sharing is crucial for sustained research and development of medical countermeasures such as diagnostics, therapeutics, and vaccines. In the case of Zika virus, although a global framework for specimen and data sharing to advance research and development is highly desirable, challenges related to legal, ethical, and intellectual property issues persist. Since the 2015-16 Zika virus outbreak, regional laboratory networks and research partnerships have made some progress in specimen and data sharing among some Zika virus-endemic countries. Pragmatic steps such as securing funds for augmenting laboratory capacity, building biobanks within public health laboratory infrastructures in low-income and middle-income countries, clearly defining the specimens and data that need to be collected, developing standardised protocols, harmonising data system interoperability to facilitate sharing, and defining mechanisms for benefit sharing will pave the way for timely development and deployment of medical countermeasures in public health emergencies.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101057"},"PeriodicalIF":20.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}